CoChat
Sign Up
Cited by 453

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer

Matsumura, T, Sugimachi, K, Iinuma, H, Takahashi, Y, Kurashige, J, Sawada, G, Ueda, M, Uchi, R, Ueo, H, Takano, Y, Shinden, Y, Eguchi, H, Yamamoto, H, Doki, Y, Mori, M, Ochiya, T, Mimori, K·2015·British Journal of Cancer
DOI 10.1038/bjc.2015.201PMC PMC4506387
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2015.201

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Expression of six microRNAs in the miR-17-92 cluster. Quantitative RT–PCR using Taqman miRNA assays was used to investigate the expression of the six miRNAs in exosomes purified from serum. The obtained values were normalised to hsa-miR-16a as an internal control. (A) Expression of 6 serum exosomal miRNAs in 6 healthy volunteers and 90 patients with CRC. (B) Expression of serum exosomal miR-19a in healthy individuals and patients with different stages of CRC. (C) Expression of serum exosomal miR-92a in healthy individuals and patients with different stages of CRC.
Figure 1 Expression of six microRNAs in the miR-17-92 cluster. Quantitative RT–PCR using Taqman miRNA assays was used to investigate the expression of the six miRNAs in exosomes purified from serum. The obtained values were normalised to hsa-miR-16a as an internal control. (A) Expression of 6 serum exosomal miRNAs in 6 healthy volunteers and 90 patients with CRC. (B) Expression of serum exosomal miR-19a in healthy individuals and patients with different stages of CRC. (C) Expression of serum exosomal miR-92a in healthy individuals and patients with different stages of CRC.CC BY-NC-SA · PubMed Central
Figure 2 Kaplan–Meier survival curves for CRC patients classified according to the miR-19a expression level. (A) Overall survival curve of 209 patients with CRC. Two groups were divided according to the average exosomal miR-19a expression level in serum of healthy individual. Patients with high expression of exosomal miR-19a in serum had significantly poorer prognoses than patients with low expression of exosomal miR-19a. (B) Disease-free survival curve for 164 patients with CRC.
Figure 2 Kaplan–Meier survival curves for CRC patients classified according to the miR-19a expression level. (A) Overall survival curve of 209 patients with CRC. Two groups were divided according to the average exosomal miR-19a expression level in serum of healthy individual. Patients with high expression of exosomal miR-19a in serum had significantly poorer prognoses than patients with low expression of exosomal miR-19a. (B) Disease-free survival curve for 164 patients with CRC.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 32

  1. Akiyoshi T, Kobunai T, Watanabe T (2012) Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today 42 (11): 1037–1045. · DOI
  2. Amano R, Yamada N, Nakata B, Kimura K, Yashiro M, Ohira M, Hirakawa K (2014) Prognostic indicator for the resection of liver metastasis of colorectal cancer. Surg Today 44 (7): 1287–1292. · DOI
  3. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6 (11): 857–866. · DOI
  4. Cortez MA, Welsh JW, Calin GA (2012) Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res 195: 151–161. · DOI
  5. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N (2008) Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9: 76. · DOI
  6. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B, Meijer GA (2009) MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 101 (4): 707–714. · DOI
  7. Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P, Yu Z (2014) miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res 33: 67. · DOI
  8. Field K, Lipton L (2007) Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 13 (28): 3806–3815. · DOI
  9. Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z (2014) miRNA in plasma exosome is stable under different storage conditions. Molecules 19 (2): 1568–1575. · DOI
  10. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65 (21): 9628–9632. · DOI
  11. Hoshino I, Matsubara H (2013) MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today 43 (5): 467–478. · DOI
  12. Komatsu S, Ichikawa D, Hirajima S, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Yagi N, Otsuji E (2014) Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma. Br J Cancer 111 (8): 1614–1624. · DOI
  13. Kowal J, Tkach M, Thery C (2014) Biogenesis and secretion of exosomes. Curr Opin Cell Biol 29: 116–125. · DOI · Paper page
  14. Li Z, Rana TM (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13 (8): 622–638. · DOI
  15. Liang Z, Li Y, Huang K, Wagar N, Shim H (2011) Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 28 (12): 3091–3100. · DOI
  16. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12: R41. · DOI
  17. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23 (24): 2839–2849. · DOI
  18. Olive V, Jiang I, He L (2010) mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42 (8): 1348–1354. · DOI
  19. Palma J, Yaddanapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML, Duelli DM (2012) MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res 40 (18): 9125–9138. · DOI
  20. Pan BT, Johnstone RM (1983) Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 33 (3): 967–978. · DOI
  21. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380 (9856): 1840–1850. · DOI
  22. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, Shinden Y, Iguchi T, Eguchi H, Shirabe K, Ochiya T, Maehara Y, Mimori K (2015) Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 112 (3): 532–538. · DOI · Paper page
  23. Tan W, Li Y, Lim SG, Tan TM (2014) miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol 20 (20): 5962–5972. · DOI
  24. Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, Watanabe M, Baba H (2013) Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119 (6): 1159–1167. · DOI · Paper page
  25. van der Meel R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM (2014) Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release 195: 72–85. · DOI
  26. Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D (2013) MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 434 (3): 688–694. · DOI
  27. Xue W, Dahlman JE, Tammela T, Khan OF, Sood S, Dave A, Cai W, Chirino LM, Yang GR, Bronson R, Crowley DG, Sahay G, Schroeder A, Langer R, Anderson DG, Jacks T (2014) Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 111 (34): E3553–E3561. · DOI
  28. Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, Horii R, Fukuoka Y, Kato T, Kosaka N, Ochiya T (2011) An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer 10: 135. · DOI
  29. Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, Furuta K, Nakajima T, Hayashi H, Sugisaki H, Higashimoto H, Kato T, Takeshita F, Ochiya T (2014a) Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun 5: 3591. · DOI
  30. Yoshioka Y, Uehara K, Ebata T, Yokoyama Y, Mitsuma A, Ando Y, Nagino M (2014b) Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surg Today 44 (7): 1300–1306. · DOI
  31. Zhang J, Xiao Z, Lai D, Sun J, He C, Chu Z, Ye H, Chen S, Wang J (2012) miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer 107 (2): 352–359. · DOI
  32. Zheng G, Du L, Yang X, Zhang X, Wang L, Yang Y, Li J, Wang C (2014) Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer 111 (10): 1985–1992. · DOI

Cited by

Sorted by citations

See all 453

Metadata

Authors
Matsumura, T., Sugimachi, K., Iinuma, H., Takahashi, Y., Kurashige, J., Sawada, G., Ueda, M., Uchi, R., Ueo, H., Takano, Y., Shinden, Y., Eguchi, H., Yamamoto, H., Doki, Y., Mori, M., Ochiya, T., & Mimori, K.
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2015-06-09
Volume
113
Issue
2
Pages
275-281
ISSN
  • 0007-0920
  • 1532-1827
DOI
10.1038/bjc.2015.201
PMC
PMC4506387
Cited by
453
References
3
Language
en
Licence
creativecommons.org/licenses/by-nc-sa/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review